Kathryn A Wyman-Chick1,2, Lauren R O'Keefe2, Daniel Weintraub3,4, Melissa J Armstrong5,6, Michael Rosenbloom1,2, Phillip K Martin7, Terry R Barclay1,2, Matthew J Barrett8. 1. 7126HealthPartners Center for Memory and Aging, Saint Paul, MN, USA. 2. 51441HealthPartners Institute, Bloomington, MN, USA. 3. 14640University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 4. Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. 5. 12233University of Florida College of Medicine, Gainesville, FL, USA. 6. Fixel Institute for Neurologic Diseases, University of Florida, Gainesville, FL, USA. 7. 12251University of Kansas School of Medicine-Wichita, KS, USA. 8. 6886Virginia Commonwealth University, Richmond, VA, USA.
Abstract
BACKGROUND: Research criteria for prodromal dementia with Lewy bodies (DLB) were published in 2020, but little is known regarding prodromal DLB in clinical settings. METHODS: We identified non-demented participants without neurodegenerative disease from the National Alzheimer's Coordinating Center Uniform Data Set who converted to DLB at a subsequent visit. Prevalence of neuropsychiatric and motor symptoms were examined up to 5 years prior to DLB diagnosis. RESULTS: The sample included 116 participants clinically diagnosed with DLB and 348 age and sex-matched (1:3) Healthy Controls. Motor slowing was present in approximately 70% of participants 3 years prior to DLB diagnosis. In the prodromal phase, 50% of DLB participants demonstrated gait disorder, 70% had rigidity, 20% endorsed visual hallucinations, and over 50% of participants endorsed REM sleep behavior disorder. Apathy, depression, and anxiety were common prodromal neuropsychiatric symptoms. The presence of 1+ core clinical features of DLB in combination with apathy, depression, or anxiety resulted in the greatest AUC (0.815; 95% CI: 0.767, 0.865) for distinguishing HC from prodromal DLB 1 year prior to diagnosis. The presence of 2+ core clinical features was also accurate in differentiating between groups (AUC = 0.806; 95% CI: 0.756, 0.855). CONCLUSION: A wide range of motor, neuropsychiatric and other core clinical symptoms are common in prodromal DLB. A combination of core clinical features, neuropsychiatric symptoms and cognitive impairment can accurately differentiate DLB from normal aging prior to dementia onset.
BACKGROUND: Research criteria for prodromal dementia with Lewy bodies (DLB) were published in 2020, but little is known regarding prodromal DLB in clinical settings. METHODS: We identified non-demented participants without neurodegenerative disease from the National Alzheimer's Coordinating Center Uniform Data Set who converted to DLB at a subsequent visit. Prevalence of neuropsychiatric and motor symptoms were examined up to 5 years prior to DLB diagnosis. RESULTS: The sample included 116 participants clinically diagnosed with DLB and 348 age and sex-matched (1:3) Healthy Controls. Motor slowing was present in approximately 70% of participants 3 years prior to DLB diagnosis. In the prodromal phase, 50% of DLB participants demonstrated gait disorder, 70% had rigidity, 20% endorsed visual hallucinations, and over 50% of participants endorsed REM sleep behavior disorder. Apathy, depression, and anxiety were common prodromal neuropsychiatric symptoms. The presence of 1+ core clinical features of DLB in combination with apathy, depression, or anxiety resulted in the greatest AUC (0.815; 95% CI: 0.767, 0.865) for distinguishing HC from prodromal DLB 1 year prior to diagnosis. The presence of 2+ core clinical features was also accurate in differentiating between groups (AUC = 0.806; 95% CI: 0.756, 0.855). CONCLUSION: A wide range of motor, neuropsychiatric and other core clinical symptoms are common in prodromal DLB. A combination of core clinical features, neuropsychiatric symptoms and cognitive impairment can accurately differentiate DLB from normal aging prior to dementia onset.
Entities:
Keywords:
cognitive fluctuations; dementia with lewy bodies; hallucinations; lewy body disease; parkinsonism; preclinical; sleep
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Daniel Weintraub; Lana M Chahine; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2017-10-24 Impact factor: 10.338
Authors: Philipp Mahlknecht; Alex Iranzo; Birgit Högl; Birgit Frauscher; Christoph Müller; Joan Santamaría; Eduardo Tolosa; Monica Serradell; Thomas Mitterling; Viola Gschliesser; Georg Goebel; Florian Brugger; Christoph Scherfler; Werner Poewe; Klaus Seppi Journal: Neurology Date: 2015-01-21 Impact factor: 9.910
Authors: P T Nelson; R J Kryscio; G A Jicha; E L Abner; F A Schmitt; L O Xu; G Cooper; C D Smith; W R Markesbery Journal: Neurology Date: 2009-10-06 Impact factor: 9.910
Authors: G A Jicha; F A Schmitt; E Abner; P T Nelson; G E Cooper; C D Smith; W R Markesbery Journal: Neurobiol Aging Date: 2008-11-20 Impact factor: 4.673
Authors: Ian G McKeith; Tanis J Ferman; Alan J Thomas; Frédéric Blanc; Bradley F Boeve; Hiroshige Fujishiro; Kejal Kantarci; Cristina Muscio; John T O'Brien; Ronald B Postuma; Dag Aarsland; Clive Ballard; Laura Bonanni; Paul Donaghy; Murat Emre; James E Galvin; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Lawrence S Honig; Manabu Ikeda; James B Leverenz; Simon J G Lewis; Karen S Marder; Mario Masellis; David P Salmon; John Paul Taylor; Debby W Tsuang; Zuzana Walker; Pietro Tiraboschi Journal: Neurology Date: 2020-04-02 Impact factor: 9.910
Authors: Ajenthan Surendranathan; Joseph P M Kane; Allison Bentley; Sally A H Barker; John-Paul Taylor; Alan J Thomas; Louise M Allan; Richard J McNally; Peter W James; Ian G McKeith; David J Burn; John T O'Brien Journal: BJPsych Open Date: 2020-06-16